SequelSEC

DBV Technologies S.A. DBVT

Biological Products, (No Diagnostic Substances) · CIK 0001613780 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.84M
Fiscal year ended 2026-09-30
Operating income
-$208.36M
Fiscal year ended 2026-09-30
Free cash flow
-$191.71M
Fiscal year ended 2026-09-30

Valuation, from the filing

Public float$250.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.85Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue44.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
FCF margin-2159.6%21th
R&D / revenue2070.3%74th
Net margin-2607.3%26th
Operating margin-2609.2%27th
CapEx / revenue9.4%70th
Revenue YoY growth35.8%67th
SBC / revenue95.6%67th
Current ratio3.67x43th

DBV Technologies S.A. (DBVT) reported revenue of $3.84M and net income of -$207.35M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from DBV Technologies S.A.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

DBV Technologies S.A. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Revenue$3.84M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$208.36M
Net income-$207.35M
Research & development$144.48M
Weighted-average diluted sharesUnavailable
Pretax income-$206.26M
Income tax expense$1.09M
Diluted EPSUnavailable
Selling, general & administrative$67.51M
General & administrative$50.59M
Selling & marketing$16.92M

Balance

DBV Technologies S.A. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Cash & equivalents$165.70M
Total assets$215.40M
Current assets$189.60M
Total liabilities$66.70M
Current liabilities$58.50M
Total equity incl. NCI$148.60M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debt$200.00K
Accounts payableUnavailable

Cash flow

DBV Technologies S.A. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Operating cash flow-$188.38M
Capital expenditures$3.33M
Investing cash flow-$6.87M
Financing cash flow$296.18M
Net change in cash$95.81M
Stock-based compensation$12.79M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

DBV Technologies S.A. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-09-30
Free cash flow-$191.71M
Gross marginUnavailable
Operating margin-5431.6%
FCF margin-4997.7%
SBC / revenue333.3%
Current ratio3.24x
Revenue YoY growth-31.6%
Net margin-5405.3%
R&D / revenue3766.5%
CapEx / revenue86.9%
Long-term debt / equity0.00x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DBVT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-28View SEC filing
10-Q · Filed 2026-07-16View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.